Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M151,741Revenue $M11,202Net Margin (%)45.5Z-Score8.9
Enterprise Value $M155,133EPS $1.8Operating Margin %58.6F-Score8
P/E(ttm))17.8Cash Flow Per Share $4.3Pre-tax Margin (%)56.7Higher ROA y-yY
Price/Book11.210-y EBITDA Growth Rate %0Quick Ratio1.8Cash flow > EarningsY
Price/Sales8.15-y EBITDA Growth Rate %8.2Current Ratio2.1Lower Leverage y-yN
Price/Cash Flow17.4y-y EBITDA Growth Rate %176ROA % (ttm)35.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)72.0Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M1,512ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDRonald Muhlenkamp 2014-09-30 Add1.19%$85.07 - $109.43
($97.98)
$ 100.583%Add 42.59%206,350
GILDJoel Greenblatt 2014-09-30 Add0.21%$85.07 - $109.43
($97.98)
$ 100.583%Add 42.28%664,223
GILDDavid Dreman 2014-09-30 Buy 0.02%$85.07 - $109.43
($97.98)
$ 100.583%New holding, 2388 sh.2,388
GILDJohn Burbank 2014-09-30 Add0.01%$85.07 - $109.43
($97.98)
$ 100.583%Add 219.9%12,073
GILDDodge & Cox 2014-09-30 Buy $85.07 - $109.43
($97.98)
$ 100.583%New holding, 4800 sh.4,800
GILDKen Heebner 2014-09-30 Reduce-0.33%$85.07 - $109.43
($97.98)
$ 100.583%Reduce -8.77%1,560,000
GILDVanguard Health Care Fund 2014-09-30 Reduce-0.28%$85.07 - $109.43
($97.98)
$ 100.583%Reduce -76.79%379,200
GILDRay Dalio 2014-09-30 Reduce-0.07%$85.07 - $109.43
($97.98)
$ 100.583%Reduce -30.96%241,521
GILDKen Fisher 2014-09-30 Reduce-0.04%$85.07 - $109.43
($97.98)
$ 100.583%Reduce -21.74%763,423
GILDKen Heebner 2014-06-30 Buy 3.8%$65.48 - $83.02
($77.76)
$ 100.5829%New holding, 1710000 sh.1,710,000
GILDJulian Robertson 2014-06-30 Add2.98%$65.48 - $83.02
($77.76)
$ 100.5829%Add 28.55%443,911
GILDJoel Greenblatt 2014-06-30 Buy 0.48%$65.48 - $83.02
($77.76)
$ 100.5829%New holding, 466853 sh.466,853
GILDJohn Rogers 2014-06-30 Add0.25%$65.48 - $83.02
($77.76)
$ 100.5829%Add 60.78%638,734
GILDKen Fisher 2014-06-30 Add0.07%$65.48 - $83.02
($77.76)
$ 100.5829%Add 62.11%975,483
GILDRay Dalio 2014-06-30 Add0.06%$65.48 - $83.02
($77.76)
$ 100.5829%Add 41.22%349,821
GILDRonald Muhlenkamp 2014-06-30 Reduce-0.59%$65.48 - $83.02
($77.76)
$ 100.5829%Reduce -24.63%144,715
GILDVanguard Health Care Fund 2014-06-30 Reduce-0.21%$65.48 - $83.02
($77.76)
$ 100.5829%Reduce -39.79%1,633,700
GILDGeorge Soros 2014-06-30 Sold Out -0.04%$65.48 - $83.02
($77.76)
$ 100.5829%Sold Out0
GILDMariko Gordon 2014-06-30 Reduce-0.02%$65.48 - $83.02
($77.76)
$ 100.5829%Reduce -35.57%11,654
GILDJulian Robertson 2014-03-31 Add0.59%$68.55 - $83.95
($78.44)
$ 100.5828%Add 7.91%345,320
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD David Dreman 2014-09-302,38800.02New Buy
GILD Dodge & Cox 2014-09-304,80000New Buy
GILD John Burbank 2014-09-3012,07300.02+219.9%
GILD Ronald Muhlenkamp 2014-09-30206,3500.014+42.59%
GILD Joel Greenblatt 2014-09-30664,2230.040.7+42.28%
GILD John Rogers 2014-09-30643,8960.040.88+0.81%
GILD Julian Robertson 2014-09-30443,9110.0312.5
GILD Jean-Marie Eveillard 2014-09-3040000
GILD Ken Heebner 2014-09-301,560,0000.14.7-8.77%
GILD Mariko Gordon 2014-09-3010,36600.05-11.05%
GILD Mario Gabelli 2014-09-3042,60000.02-13.36%
GILD Ken Fisher 2014-09-30763,4230.050.17-21.74%
GILD Ray Dalio 2014-09-30241,5210.020.2-30.96%
GILD Vanguard Health Care Fund 2014-09-30379,2000.030.1-76.79%
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MILLIGAN JOHN FPresident and COO 2014-11-07Sell146,895$107.37-6.31view
Whitley Richard JamesDirector 2014-11-03Sell5,000$112.02-10.2view
Washington Robin LEVP, CFO 2014-11-03Sell33,192$110.26-8.77view
Alton Gregg HEVP, Corp & Med Affairs 2014-11-03Sell33,000$110.5-8.97view
Carter Paul RutherfordEVP Commercial Ops 2014-11-03Sell3,000$112.46-10.55view
MARTIN JOHN CChairman and CEO 2014-11-03Sell140,625$110.4-8.89view
Carter Paul RutherfordEVP Commercial Ops 2014-10-24Sell2,000$110-8.55view
Cogan John FrancisDirector 2014-10-21Sell15,000$104.08-3.35view
MILLIGAN JOHN FPresident and COO 2014-10-07Sell146,895$104.6-3.83view
Whitley Richard JamesDirector 2014-10-01Sell5,000$106.99-5.98view

Press Releases about GILD :

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Tableau Software Inc, Gilead Sciences Inc, Facebook Inc. Nov 16 2014 
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
Gilead Sciences Can Sustain Its Impressive Performance in the Long Run Nov 11 2014 
Why Gilead Sciences' Bull Run Should Continue Nov 06 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Gilead Sciences has Multiple Growth Drivers Oct 31 2014 
Is Gilead Sciences a Worthy Investment? Oct 30 2014 
Gilead Sciences – From The Long Term Perspective Oct 08 2014 
There's More to Gilead Sciences than a Successful Drug Sep 26 2014 
A Few Reasons Why AbbVie's Momentum Will Continue Sep 25 2014 


More From Other Websites
Gilead to Buy Knight Therapeutics' Priority Review Voucher Nov 20 2014
Ooh La La: France Negotiates a Steep Discount for Sovaldi From Gilead Nov 20 2014
France pegs Gilead hepatitis C drug at "lowest price in Europe" Nov 20 2014
Gilead Gains on Harvoni's EU Approval for HCV Treatment Nov 19 2014
How Much? Gilead Pays $125M For an FDA Priority Review Voucher Nov 19 2014
Gilead Sciences: The Worst Case Scenario? Nov 19 2014
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU Nov 19 2014
The Buzziest Biotech Stocks on Social Media Nov 18 2014
Stock Movers: Why 4 Big Drug Stocks Are Rising Today Nov 18 2014
Gilead Sciences: Harvoni Gets European Marketing OK Nov 18 2014
Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni Nov 18 2014
European Commission Grants Marketing Authorization for Gilead’s Harvoni®?... Nov 18 2014
European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼... Nov 18 2014
GILEAD SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Nov 17 2014
Incyte Building Blockbuster Drug One Disease At A Time Nov 17 2014
Gilead: What About Its Pipeline? Nov 17 2014
Biotech Stocks Hit: Stock Market To See New Leaders? Nov 14 2014
Biotech correction coming? 16 trades, 55 seconds Nov 14 2014
US STOCKS-Wall St posts gains for 4th week; ends flat for day Nov 14 2014
All in all, another solid week for U.S. equities... Nov 14 2014
US STOCKS-Wall St inches lower with healthcare shares Nov 14 2014
GILEAD SCIENCES INC Financials Nov 14 2014
Can Gilead Double From Here? Nov 14 2014
Are Health Care Funds Taking PEDs? Nov 13 2014
Which Health Care ETF Should You Buy? Nov 13 2014
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for... Nov 11 2014
Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease... Nov 11 2014
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide... Nov 06 2014
Gilead beats Street 3Q forecasts Oct 28 2014
DMG MORI SEIKI increases income Group confirms its forecast for the financial year 2014 Oct 28 2014
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 Oct 21 2014
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the... Oct 16 2014
US STOCKS- S&P 500, Nasdaq break 3-day slide but Dow dips Oct 14 2014
US STOCKS-Dow, S&P 500 briefly turn negative as energy weighs Oct 14 2014
New once-a-day pill for hepatitis C wins FDA OK Oct 10 2014
US STOCKS-Biotechs climb after two-day drop Sep 24 2014
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for... Sep 23 2014
Gilead slashes cost of $1,000-a-pill hepatitis drug for poor nations Sep 15 2014
US STOCKS-Wall St little changed but tech weighs on Nasdaq Sep 15 2014
US STOCKS-Biotechs on track for 3rd straight decline as Gilead drags Sep 15 2014
Gilead to expand access to Hepatitis C drugs in developing world Sep 15 2014
Gilead to license generic version of Sovaldi Sep 15 2014
Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others Sep 15 2014
Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others Sep 15 2014
Gilead slashes cost of $1,000-a-pill hepatitis drug for poor nations Sep 15 2014
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in... Sep 15 2014
Gilead to expand access to Hepatitis C drugs in developing world Sep 14 2014
Achillion rises on hepatitis C drug study Aug 15 2014
UK cost body backs pricey Gilead hepatitis pill for some patients Aug 14 2014
$1,000 Sovaldi now hepatitis treatment of choice Jul 29 2014
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing... Jul 23 2014
Gilead profit more than quadruples on hep C drug Jul 23 2014
Gilead 2Q profit more than quadruples Jul 23 2014
FDA approves Gilead Sciences drug for 3 cancers Jul 23 2014
Singapore investor Temasek upbeat on China, seeks more bank, tech investments Jul 08 2014
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for... Jun 27 2014
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir... Jun 15 2014
Gilead profit triples, hepatitis C drug sales beat by $1 billion Apr 22 2014
Gilead says 1Q sales of Sovaldi totaled $2.27B Apr 22 2014
Earnings, big pharma deals give S&P 500 6th straight gain Apr 22 2014
US STOCKS-Earnings lift S&P 500, Nasdaq; S&P's best week since July Apr 17 2014
Natco seeks to block Gilead's hepatitis C drug patent in India - source Apr 10 2014
Natco seeks to block Gilead's hepatitis C drug patent in India - source Apr 10 2014
Gilead aims to license hepatitis C drug to 3-4 Indian firms Apr 08 2014
Gilead aims to license hepatitis C drug to 3-4 Indian firms Apr 08 2014
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan Apr 02 2014
US stocks finish higher; biotech sector steadies Mar 25 2014
Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe Mar 14 2014
Medical groups question price of new hep C drug Mar 11 2014
Us close: S&P 500 hits another high as jobless claims fall Mar 07 2014
Gilead Sciences to Present at Two Upcoming Investor Conferences Feb 11 2014
Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1... Feb 11 2014
US close: Stocks push higher ahead of Yellen speech Feb 11 2014
Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results Feb 07 2014
US close: Stocks gain most in seven weeks as jobless claims decline Feb 07 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK